Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury

Massimo Collino a, *, Mara Rogazzo a, Alessandro Pini b, Elisa Benetti a, Arianna Carolina Rosa a, Fausto Chiazza a, Roberto Fantozzi a, Daniele Bani b, Emanuela Masini c

a Department of Drug Science and Technology, University of Turin, Turin, Italy
b Department of Experimental and Clinical Medicine, Research Unit of Histology and Embriology, University of Florence, Florence, Italy
c Department of NEUROFARBA, Section of Pharmacology, University of Florence, Florence, Italy

Received: April 12, 2013; Accepted: July 24, 2013

Abstract

Although recent preclinical and clinical studies have demonstrated that recombinant human relaxin (rhRLX) may have important therapeutic potential in acute heart failure and chronic kidney diseases, the effects of acute rhRLX administration against renal ischaemia/reperfusion (I/R) injury have never been investigated. Using a rat model of 1-hr bilateral renal artery occlusion followed by 6-hr reperfusion, we investigated the effects of rhRLX (5 μg/Kg i.v.) given both at the beginning and after 3 hrs of reperfusion. Acute rhRLX administration attenuated the functional renal injury (increase in serum urea and creatinine), glomerular dysfunction (decrease in creatinine clearance) and tubular dysfunction (increase in urinary excretion of N-acetyl-β-glucosaminidase) evoked by renal I/R. These beneficial effects were accompanied by a significant reduction in local lipid peroxidation, free radical-induced DNA damage and increase in the expression/activity of the endogenous antioxidant enzymes Mn- and CuZn-superoxide dismutases (SOD). Furthermore, rhRLX administration attenuated the increase in leucocyte activation, as suggested by inhibition of myeloperoxidase activity, intercellular-adhesion-molecule-1 expression, interleukin (IL)-1β, IL-18 and tumour necrosis factor-α production as well as increase in IL-10 production. Interestingly, the reduced oxidative stress status and neutrophil activation here reported were associated with rhRLX-induced activation of endothelial nitric oxide synthase and up-regulation of inducible nitric oxide synthase, possibly secondary to activation of Akt and the extracellular signal-regulated protein kinase (ERK) 1/2, respectively. Thus, we report herein that rhRLX protects the kidney against I/R injury by a mechanism that involves changes in nitric oxide signalling pathway.

Keywords: relaxin • renal ischaemia/reperfusion • acute kidney injury • inflammation

Introduction

Since its discovery in 1926, relaxin (RLX) has long been regarded as a peptide hormone of ovarian origin involved in the peripartum widening of the pubic symphysis. Subsequently, growing evidence has suggested that RLX may exert a broad range of biological effects on many organs and apparatuses, especially the cardiovascular system [1]. In animal models, RLX has been reported to increase blood perfusion and reduce myocardial, cerebral, intestinal and pulmonary ischaemic damage [2-6]. In humans, clinical trials studying intravenous recombinant human relaxin (rhRLX) as a treatment for patients hospitalized with acute heart failure have recently shown significant improvement in clinical outcome without any major adverse events [7, 8]. The effects of rhRLX treatment on placental blood flow, maternal blood pressure and renal function are also being evaluated in women with preeclampsia, a condition of new-onset hypertension and proteinuria during pregnancy [9, 10].

The specific mechanisms by which RLX mediates its cardiovascular effects have still to be fully understood, but are key to identifying novel targets that may be used to enhance its therapeutic potential. Relaxin is a member of the relaxin peptide family, which, in humans, encompasses H1, H2 and H3 RLXs as well as insulin like peptides (INSL) 3, 5 and 6. The main circulating isoform is H2, equivalent to other species’ relaxin-1, commonly referred to as RLX. Relaxin family peptides target specific G-protein-coupled receptors, defined relaxin...
family peptide receptors (RXFP), of which RXFP1 is currently consid-
ered the main and specific H2 RLX receptor [11]. Recently, both RLX
peptide and its receptor RXFP1 have been identified in the renal
medulla and cortex, thus suggesting that the kidney is both a potential
source and a target organ for RLX activity [12]. Exogenous RLX
administration has been reported to reduce the progression of dis-
esases in several experimental models of renal fibrosis and the
absence of endogenous RLX may contribute to the development of
spontaneous fibrosis [13]. In addition to its well-documented antifib-
rotic actions, RLX has been shown to increase renal plasma flow and
glomerular filtration rate, attenuate the renal circulatory response to
angiotensin II and reduce plasma osmolality [14]. Although various
effects of RLX in renal diseases have been discovered, the potential
role of RLX in renal ischaemia/reperfusion injury (I/R), one of the
most common causes of acute kidney injury (AKI), has not yet been
investigated. Acute kidney injury is a major kidney disease associated
with high mortality and morbidity and several large epidemiological
studies have linked AKI with the later development of chronic and
end-stage kidney diseases [15]. Unfortunately, pharmacological inter-
ventions are limited and there is currently no successful therapy,
except for supportive care. Thus, this study was designed (i) to inves-
tigate the effects of rhRLX-2 on renal dysfunction and injury evoked
by I/R in the rat and (ii) to better elucidate the signalling mechanism
(s) by which RLX exerts its effects on the kidney.

Materials and methods

Animals and surgery

Male Wistar rats (Harlan-Italy; Udine, Italy) were fed a Piccioni pellet
diet (n.48, Gessate Milanese, Italy) and water ad libitum. Animal care
was in compliance with Italian regulations on the protection of animals
used for experimental and other scientific purposes (D.M. 116/92). The
renal I/R protocol, approved by the Turin University Ethics Commit-
tee, was employed in multiple previous reports from our laboratory. The
renal I/R protocol here described has been approved by the Turin Uni-
versity Ethics Committee and it was employed in multiple previous
reports from our laboratory. The experimental protocol, approved by the Turin University Ethics Commit-
tee, was employed in multiple previous reports from our laboratory. The

Measurement of biochemical parameters

At the end of the reperfusion period, 1 ml blood samples were collected
and centrifuged (10,000 × g for 10 min.) to separate the serum, from
which biochemical parameters were measured within 24 hrs. The vol-
ume of urine produced was determined using the urine collected during
the reperfusion period. Serum and urine creatinine concentrations were
measured spectrophotometrically at 490 nm by the Jaffé kinetic reac-
tion, using commercially available kits. Renal creatinine clearance was
calculated by the standard formula C = (U × V)/P, where U is the con-
centration in urine, V is urine flow rate and P is the plasma concentra-
tion. Serum urea and creatinine concentrations and creatinine clearance
were used as indicators of impaired renal function. N-acetyl-beta-glucosa-
mimidase (NAG) was measured in the urine of experimental rats by a
colorimetric assay (Roche Diagnostics, Mannheim, Germany) and was
used as marker of tubular injury [22].

Histopathological examination and tissue injury scoring

Histopathological analysis was carried out on whole kidney cryostat cross-
sections stained with either haematoxylin-eosin or Periodic acid-Schiff (PAS)
staining for glycoproteins. The used severity scoring criteria are reported in
Table 1. Each animal was assigned a separate score for glomeruli, tubuli and
blood vessel injury, evaluated by two independent observers (D.B. & A.P.)
blinded to the experimental groups, and the values were then averaged.
**Determination of thiobarbituric acid-reactive substances**

Thiobarbituric acid-reactive substances (TBARS) are end-products of cell membrane lipid peroxidation by reactive oxygen species (ROS) and are considered a reliable marker of oxidative stress-induced cell damage. Thiobarbituric acid-reactive substances were determined by measurement of the chromogen obtained from the reaction of malondialdehyde with 2-thiobarbituric acid according to Aruoma et al. [23].

**Determination of 8-Hydroxy-2′-deoxyGuanosine**

DNA isolation from cardiac tissue homogenates was performed according to Masini et al. [4]. Samples of DNA extract were used for 8-Hydroxy-2′-deoxyGuanosine (8-OHdG) determination with a Bioxytech enzyme immunoassay kit (Oxis, Portland, OR, USA), following the instructions provided by the manufacturer. The values are expressed as ng 8-OHdG/g proteins.

**Measurement of Mn- and CuZn-superoxide dismutase activities**

Kidney samples were homogenized with 10 mM PBS, pH 7.4, sonicated on ice (three times, 20 sec.) and centrifuged at 100,000 g for 10 min. Superoxide dismutases (SOD) activity was measured in the supernatants as described by Nishida et al. [24], with minor modifications. The assay is based on the inhibition of nitro blue tetrazolium conversion by SOD into a blue tetrazolium salt, mediated by superoxide radicals, which are generated by xanthine oxidase. The amount required to inhibit the rate of reduction of nitro blue tetrazolium by 50% was defined as one unit of enzyme activity. Total SOD activity was determined by monitoring the rate of reduction of nitroblue tetrazolium. Activity of MnSOD was measured in the presence of 5 mM sodium cyanide and activity of CuZnSOD was calculated by subtracting MnSOD activity from total SOD activity.

**Myeloperoxidase activity**

Myeloperoxidase activity, used as an indicator of leucocyte accumulation into the kidney, was determined as previously described [17]. Briefly, samples were homogenized and centrifuged for 30 min. at 13,000 × g at 4°C. An aliquot of the supernatant was then allowed to react with a solution of 1.6 mM tetramethylbenzidine and 0.1 mM H₂O₂. The rate of change in absorbance was measured spectrophotometrically at 460 nm. Myeloperoxidase activity was defined as the quantity of enzyme degrading 1 µmol of peroxide/min. at 37°C and was expressed in milliunits/g of wet tissue.

**Determination of interleukin (IL)-1β, IL.18, tumour necrosis factor (TNF)-α and IL-10 production**

Cytokines were measured with commercial ELISA kits (Cayman Chemical, Ann Arbor, MI, USA), following the protocol provided by the manufacturer.

**Western blot analysis**

Western blots were carried out as previously described [25]. Proteins were separated by 8% sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to polyvinylidenedifluoride membrane, which was then incubated with primary antibodies (goat anti-ICAM-1, mouse anti-phERK, rabbit anti-ERK, rabbit anti-iNOS, mouse anti-phAkt, rabbit anti Akt, goat anti-ph-eNOS, rabbit anti-eNOS, goat anti-CuZnSOD, rabbit anti-MnSOD). Blots were then incubated with a secondary antibody conjugated with horseradish peroxidase (dilution 1:10,000) and developed with the enhanced chemiluminescence (ECL) detection system. The immunoreactive bands were visualized by autoradiography and the density of the bands was evaluated densitometrically using Gel ProAnalyzer 4.5, 2000 software (Media Cybernetics, Silver Spring, MD, USA). The membranes were stripped and incubated with β-actin monoclonal antibody (dilution 1:5000) and subsequently with an anti-mouse antibody (dilution 1:10,000) to assess gel-loading homogeneity.

**Materials**

Unless otherwise stated, all compounds were purchased from the Sigma-Aldrich Company Ltd. (St Louis, MO, USA). Clinical grade human recombinant H2 RLX was kindly provided by Prof. Mario Bigazzi (Foundation for the Research on Relaxin in Cardiovascular and Other Diseases, Prosperus Institute, Florence, Italy). The bicinechonic acid Protein Assay kit and SuperBlock blocking buffer were from Pierce Biotechnology Inc. (Rockford, IL, USA). Antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Luminol ECL was from Amersham (Buckinghamshire, United Kingdom).

**Table 1 Histopathological scoring criteria**

| Grade | Glomeruli | Proximal/distal tubuli | Blood vessels |
|-------|-----------|------------------------|--------------|
| 0     | Normal    | Normal                 | Normal       |
| 1     | Microvacuolation | Microvacuolation | Focal dilation and blood stasis |
| 2     | Vacuolation | Vacuolation, ruffled border disappearance, cell shedding, rare casts | Diffuse dilation and blood stasis |
| 3     | Vacuolation, cell shedding, enlargement of Bowman capsule | Vacuolation, diffuse cell detachment, many casts | Diffuse, severe dilation and blood stasis, interstitial haemorrhage |
Statistical analysis

All values in both the text and figures are expressed as mean ± SEM for n observations. One-way ANOVA with Dunnett’s post-test was performed with the GraphPad Prism Software (San Diego, CA, USA) and P values below 0.05 were considered significant.

Results

Effect of acute rhRLX administration on I/R-induced renal dysfunction

Rats that underwent renal I/R exhibited a significant increase in serum levels of urea and creatinine, compared with sham-operated rats (Fig. 1A and B respectively). To discount the possibility of a rapid increase in serum creatinine levels because of increased release of creatinine from muscle during I/R, creatinine clearance was also measured. Ischaemia/reperfusion exposure led to a drastic decrease in creatinine clearance (Fig. 1C) as well as in urine flow (Fig. 1D). Interestingly, administration of rhRLX during reperfusion prevented the increase in the serum concentrations of urea and creatinine and resulted in a significant increase in creatinine clearance and urine flow (Fig. 1A–D), thus indicating improvement in renal injury and glomerular dysfunction. Renal I/R evoked a significant increase in urinary NAG levels, suggesting significant tubular dysfunction, which was markedly reduced by rhRLX administration (Fig. 1E). Conversely, the administration of rhRLX to sham-operated rats had no significant effect on any of the biochemical markers measured.

Fig. 1 Effect of I/R and rhRLX on renal dysfunction evaluated on blood and urine parameters. Serum creatinine (A), urea (B), creatinine clearance (C), urine flow (D) and urinary N-acetyl-β-glucosaminidase levels (E) were measured after sham operation (Sham) or renal ischaemia-reperfusion injury (IR). Further groups of rats received rhRLX (5 μg/kg, i.v.) at the beginning of reperfusion and again after 3 hrs of reperfusion (Sham+RLX and IR+RLX). Data are expressed as mean ± SEM. *P < 0.05 versus IR.
Effects of rhRLX on the histological signs of injury caused by I/R

Figure 2 depicts representative histopathological features of the kidney (cortex and medulla) from rats belonging to the different experimental groups. When compared with the normal kidney morphology of the sham-operated rats, the samples taken from the animals undergoing renal I/R showed typical features of glomerular, tubular and vascular injury. In particular, large tissue areas in both the renal cortex and medulla showed widespread tubular cell vacuolization with reduced or absent ruffled border, accompanied by focal necrosis, shedding of the tubular epithelial lining and formation of hyaline tubular casts. The interstitial connective tissue showed very dilated microvessels filled with blood (peliosis) and sparse haemorrhage foci. Glomeruli in the renal cortex also showed cell microvacuolation and occasional blood extravasation in the Bowman capsule. Of note, rhRLX administration at reperfusion markedly reduced these renal abnormalities, the most evident changes being tubular cell microvacuolation and a moderate degree of microvascular dilatation. Semi-quantitative scoring of kidney injury performed on the histological slides confirmed the visual observations and showed that rhRLX significantly attenuates renal cell damage (Fig. 2).

Effects of rhRLX on oxidative stress induced by renal I/R injury

Rats that had undergone I/R exhibited a massive increase in tissue markers of oxidative stress, such as TBARS production, an index of peroxidation of cell membrane lipids, and 8-OHdG, a marker of free radical-induced DNA damage (Fig. 3A and B, respectively). The robust increase in TBARS and 8-OHdG levels was blunted by rhRLX administration. Renal I/R injury evoked a significant decrease in the activity of the endogenous antioxidant enzymes MnSOD and CuZnSOD (Fig. 4A and B, respectively), which was associated with a slight suppression of their protein expression (Fig. 4C and D). Interestingly, rhRLX administration almost completely abolished the I/R-induced reduction in MnSOD and CuZnSOD activities and evoked a massive protein up-regulation, above the control levels. On the other hand, rhRLX administration to sham-operated animals had no significant effect on any of the measured markers.

Effects of rhRLX on inflammatory markers

The improvement in the outcome of I/R injury was associated with a marked modulation of the leucocyte accumulation measured in kidney samples at term of reperfusion. As shown in Figure 5A, renal I/R caused a robust increase in MPO activity, a specific leucocyte marker, in comparison with sham-operated rats. In the animals treated with rhRLX during reperfusion, the MPO activity was significantly reduced. The adhesion molecule ICAM-1, which is the endothelial ligand for the neutrophil receptor CD11b/CD18, was barely detectable in the kidney from sham-operated animals, while its expression was strongly induced by I/R (Fig. 5B). Administration of rhRLX drastically reduced the I/R-induced increase in ICAM-1 expression.

Interleukin-1β, IL-18 and TNF-α, typical pro-inflammatory cytokines, were significantly increased in renal tissue of ischaemic/reperfused rats, as compared with the sham-operated animals (Fig. 6A–C respectively). Interestingly, administration of rhRLX prevented the I/R-induced rise in IL-1β, IL-18 and TNF-α, levels. When the plasmatic content of the well-known anti-inflammatory cytokine IL-10 was measured (Fig. 6D), a slight decrease in its serum level was detectable in the rats that underwent I/R injury, whereas rhRLX administration reported IL-10 concentration back to values similar to those measured in sham-operated animals.

Effect of rhRLX on ERK1/2 phosphorylation and iNOS expression in the kidneys of rats that underwent I/R injury

To gain a better insight into the potential mechanism(s) underlying the observed beneficial effects of rhRLX, we investigated the effects of this hormone on cell signalling pathways known to confer protection to the kidney and that have been previously demonstrated to mediate rhRLX effects in other organs. The phosphorylation of ERK1/2 MAPK was not significantly affected by I/R injury; however, when ischaemic/reperfused rats were treated with rhRLX, we detected a massive increase in ERK phosphorylation (Fig. 7A). As shown in Figure 7B, densitometric analysis of the Western blot bands detected low iNOS protein levels in the kidney obtained from sham-operated animals. I/R injury induced a slight increase in the expression of iNOS, which was maximum in the group of animals treated with rhRLX during reperfusion.

Effect of rhRLX on the phosphorylation of Akt and eNOS in the kidneys of rats that underwent I/R injury

When compared with sham-operated rats, rats that underwent I/R injury developed significant decreases in the phosphorylation of Akt on Ser473 in reperfused kidney samples (Fig. 8A). Therapeutic administration of rhRLX during reperfusion attenuated the decline in Akt phosphorylation caused by I/R. The degree of the phosphorylation of eNOS on Ser1177 was similar in sham-operated rats and ischaemic/reperfused rats indicating that I/R alone is not sufficient to affect eNOS phosphorylation (Fig. 8B). Treatment of ischaemic/reperfused rats with rhRLX resulted in a twofold increase in the phosphorylation of eNOS when compared with rats exposed to I/R only.

Discussion

Although recent preclinical and clinical studies have demonstrated that RLX may have important therapeutic potential in chronic kidney diseases, such as renal fibrosis and salt-sensitive hypertension, the precise mechanisms underlying the effects of the hormone on cell signalling pathways known to confer protection to the kidney and that have been previously demonstrated to mediate rhRLX effects in other organs are still largely unknown. The results of the present study suggest that rhRLX administration at reperfusion markedly reduced these renal abnormalities, the most evident changes being tubular cell microvacuolation and a moderate degree of microvascular dilatation. The observed beneficial effects of rhRLX were associated with a significant reduction in the levels of pro-inflammatory cytokines, such as IL-1β, IL-18 and TNF-α, and an increase in the levels of the anti-inflammatory cytokine IL-10. Additionally, rhRLX administration almost completely abolished the I/R-induced increase in ICAM-1 expression, a typical adhesion molecule involved in the recruitment of leucocytes to the kidney, and significantly reduced the levels of MPO activity, a specific leucocyte marker. These results are consistent with previous studies showing that rhRLX has a protective effect on the kidney, in terms of reducing renal cell damage, and reducing inflammation and oxidative stress, which are key contributors to the development of chronic kidney disease.
[26], its role in AKI has never been elucidated. The present findings offer first experimental evidence that the therapeutic administration of rhRLX at reperfusion significantly reduces renal injury and dysfunction caused by I/R in rats, while it has no effect on normal renal function in sham-operated animals. The dose of rhRLX used in this study has been previously reported to protect other organs against I/R injury and to prevent the development of acute pancreatitis [3, 27, 28]. Notably, to simulate the clinical conditions, in our experimental model, rhRLX was only applied during reperfusion, indicating that this treatment strategy could be potentially employed in several situations known to result in AKI, including renal transplantation, aortic aneurysm surgery, or X-ray contrast tracer-induced nephropathy, to protect or even rescue a kidney previously challenged by ischaemia. Our results further corroborate and extend the previous findings demonstrating that RLX is capable of ameliorating renal hemodynamics by inducing selective renal vasodilation and hyperfiltration in both rats and humans [29, 30]. In our experimental model, the improvements in the outcome of renal...
Fig. 3 Effects of I/R and rhRLX on lipid peroxidation and free radical-induced DNA in kidney samples. TBARS production (A), 8-OHdG levels (B) were measured subsequent to sham operation (Sham) or renal ischaemia–reperfusion injury (IR) in the absence (vehicle) or presence of rhRLX (5 μg/kg, i.v.; Sham+RLX and IR+RLX). Data are expressed as mean ± SEM. ★P < 0.05 versus IR.

Fig. 4 Effects of I/R and rhRLX on activity and expression of manganese-superoxide dismutases (MnSOD) and copper-zinc-superoxide dismutases (CuZnSOD) in kidney samples. Activity (A and B) and protein expression (C and D) of the SOD isoforms mitochondrial MnSOD and cytosolic CuZnSOD were measured in kidney homogenates of sham-operated rats (Sham) and rats that underwent 1-hr ischaemia and 6-hr reperfusion (IR) in the absence or presence of rhRLX (5 μg/kg, i.v.; Sham+RLX and IR+RLX). Each immunoblot is from a single experiment and is representative of three separate experiments. Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding β-actin contents and normalized using the related sham-operated band. Data are means ± SEM of three separate experiments for Western Blot and five animals/group for SOD activity. ★P < 0.05 versus IR.
Fig. 5 Effects of I/R and rhRLX on leucocyte accumulation in kidney samples. Myeloperoxidase (MPO) activity (A) and ICAM-1 expression (B) were measured in kidney homogenates of sham-operated rats (Sham) and rats that underwent 1-hr ischaemia and 6-hr reperfusion (IR) in the absence or presence of rhRLX (5 μg/kg, i.v.; Sham+RLX and IR+RLX). Each immunoblot is from a single experiment and is representative of three separate experiments. Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding β-actin contents and normalized using the related sham-operated band. Data are means ± SEM of three separate experiments for Western Blot and five animals/group for MPO. ★P < 0.05 versus IR.

Fig. 6 Effects of I/R and rhRLX on cytokine production in kidney samples. IL-1β (A), IL-18 (B), TNF-α (C) and IL-10 (D) levels were measured in the kidney of sham-operated rats (Sham) and rats that underwent 1-hr ischaemia and 6-hr reperfusion (IR) in the absence or presence of rhRLX (5 μg/kg, i.v.; Sham+RLX and IR+RLX). Data are means ± SEM of five animals/group. ★P < 0.05 versus IR.

© 2013 The Authors.
Journal of Cellular and Molecular Medicine Published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
damage by rhRLX administration were associated with a significant inhibition of both the inflammatory response and oxidative stress induced by I/R. Namely, rhRLX reduced leucocyte adhesion to ischaemic-reperfused vascular endothelium, as suggested by its ability to suppress the expression of the adhesion molecule ICAM-1 and the activity of MPO, selected as typical markers of leucocyte inflammatory recruitment, which were both drastically up-regulated by I/R. At the same time, rhRLX significantly decreased the production of TNF-α, IL-1β and IL-18 in the kidney of animals that underwent I/R injury. Interestingly, this effect was associated with increased level of the anti-inflammatory cytokine IL-10, suggesting that RLX may operate a shift from a pro-inflammatory to an anti-inflammatory status. These results are consistent with previous reports demonstrating the role of RLX as a potent inhibitory factor in early vascular inflammation with prominent inhibitory effects on the expression of cytokines and adhesion molecules [31–33]. The attenuated inflammatory response caused by rhRLX treatment may also account for the decrease in tissue markers of oxidative stress, thus supporting the notion that release of ROS from activated leucocytes provides a major contribution to peroxidation of lipid membranes and free radical-induced DNA damage in the kidney. Besides, a direct effect of RLX on oxidative stress has also been recently demonstrated by Dschietzig et al. [34], showing that RLX stimulates Cu/ZnSOD expression in rat aortic rings, by increasing the Cu/ZnSOD promoter activity at different time-points. Our find-
ings are in keeping with previous studies from our and other research groups showing that RLX exerts beneficial effects against organ ischemic damage by reducing local leucocyte recruitment and oxidative stress [3, 4, 6]. Accordingly, RLX has also been proposed as a protective substance in preservation solutions for lung and liver transplantation [5, 35, 36]. Despite these intriguing data and the evidence that the organ is of greatest uptake of exogenously administered RLX [19], the specific signal transduction pathway by which RLX exerts its effects in the kidney remains to be fully elucidated. Previous studies have demonstrated that several renal biological actions of RLX, including its potent antifibrotic effects, are mediated by functional activation of the relaxin receptor RXFP1, which is expressed by specific renal cells, such as mesangial cells and myofibroblasts [37, 38]. RXFP1 signalling is complex, involving multiple pathways depending on the cell type under investigation; however, recent evidence suggests a key role for the nitric oxide pathway in mediating major renovascular effects of RLX [39]. For instance, Sasser et al. [40] have demonstrated that RLX was ineffective in preventing chronic renal injury during administration of the nitric oxide synthase inhibitor N(o)-nitro-l-arginine methyl ester (L-NAME), suggesting that the renoprotective effects of RLX are dependent on a functional NOS system. Although the exact signalling mechanisms of RXFP1 were beyond the scope of this study, we could demonstrate an involvement of the nitric oxide pathway in the RLX-mediated effects reported here: in fact, RLX administration was associated with eNOS activation and induction of iNOS expression, resulting in enhanced formation of nitric oxide in the microcirculation. In conditions associated with I/R, the enhanced formation of nitric oxide is beneficial, as it can cause local vasodilation, inhibit adhesion of platelets and leucocytes and promote angiogenesis [41]. There is good evidence that agents that release nitric oxide or enhance the formation of endogenous nitric oxide attenuate organ injury/dysfunction in AKI [42, 43]. By a nitric oxide-dependent mechanism, RLX has been shown to strongly inhibit neutrophil activation, thereby reducing free radical generation, chemotaxis and platelet aggregation [44, 45]. Therefore, the reduced oxidative stress status and leucocyte activation here reported may be explained, at least in part, by the ability of RLX to up-regulate the NOS/nitric oxide pathway. Previous studies in cultured human endothelial cells have shown that RLX can evoke eNOS activation by phosphorylization of specific serine residues in Akt [46]. Akt is a member of the phosphoinositol 3-kinase signal transduction enzyme family which, upon phosphorylation by its upstream regulator, can modulate inflammatory responses and apoptosis [47]. A reduction in the activation of this important survival pathway has been recently demonstrated to make the kidney more susceptible to I/R insult [48, 49]. Here, we show that RLX caused a robust increase in Akt phosphorylation. This indicates a significant Akt activation, which in turn could promote eNOS phosphorylation and renal protection. An additional contribution to the regulatory effects of RLX on nitric oxide pathway may rely on its ability to affect ERK1/2 MAPK pathway, which is another important signal for cell survival [50]. ERK activation protects renal epithelial cells from oxidative injury [51] and, particularly relevant to this study, it leads to iNOS induction in renal epithelial cells [52], renal myofibroblasts [53], vascular smooth muscle cells [54] and murine macrophages [55]. As we documented increased ERK1/2 activation in the presence of RLX, we propose that MAPK activation by RLX is, at least in part, responsible for the RLX-mediated modulation of iNOS expression. However, it must be underlined that ERK1/2 and Akt activation by RLX was recorded at 6 hrs after reperfusion. As RLX has a short serum half-life in rodents [19], we cannot rule out the possibility that RLX evokes an early intracellular signalling cascade leading to late ERK and Akt activation, thus resulting in increased NOS activity/expression.

In conclusion, this study provides first experimental evidence that acute RLX administration during reperfusion attenuates the renal dysfunction and injury caused by I/R in the rat and that these renoprotective effects of RLX involve the activation of eNOS and up-regulation of iNOS, possibly secondary to activation of Akt and ERK1/2, respectively. The modulation of the nitric oxide pathway appears a crucial mechanism through which RLX selectively inhibits the inflammatory response and oxidative stress sparked by renal I/R. Overall, these findings provide further evidence to the concept that RLX may be regarded as a therapeutic tool in diseases characterized pathogenically by vascular dysfunction and impaired nitric oxide production.

Acknowledgements

The authors are grateful to Prof. Giancarlo Bartolini for precious help in kidney histopathology and to Prof. Mario Bigazzi for kind donation of the H2 RLX. This work was supported by grants from Cassa di Risparmio di Firenze.

Conflicts of interest

The authors confirm that there are no conflicts of interest.

References

1. Bani D, Bigazzi M. Relaxin as a cardiovascu-
lar drug: a promise kept. Curr Drug Saf. 2011; 6: 324–8.
2. Masini E, Bani D, Bello MG, et al. Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology; 1997; 138: 4713–20.
3. Perna AM, Masini E, Nistri S, et al. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 2005; 19: 1525–7.
4. Masini E, Cuzzocrea S, Mazzon E, et al. Protective effects of relaxin in ischemia/reper-
fusion-induced intestinal injury due to splanchnic artery occlusion. Br J Pharmacol. 2006; 148: 1124–32.
5. Alexiou K, Matschke K, Westphal A, et al. Relaxin is a candidate drug for lung preserva-
tion: relaxin-induced protection of rat lungs from ischemia-reperfusion injury. J Heart Lung Transplant. 2010; 29: 454–60.
10. Chen SA, Milne P, Saleh TM. Relaxin pretreatment decreases infarct size in male rats after middle cerebral artery occlusion. Ann N Y Acad Sci. 2005; 1041: 223–8.

11. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009; 373: 1429–39.

12. Teerlink JR, Cotler G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013; 381: 29–39.

13. Lafayette RA, Hladunewich MA, Derby G, et al. Serum relaxin levels and kidney function in late pregnancy with or without pre-eclampsia. Clin Nephrol. 2011; 75: 226–32.

14. Umenori E, Sibai B, Teichman SL. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann N Y Acad Sci. 2009; 1160: 381–4.

15. Kong RC, Shilling PJ, Lobb DK, et al. Membrane receptors: structure and function of the relaxin family peptide receptors. Mol Cell Endocrinol. 2010; 320: 1–15.

16. Samuel CS, Hewitson TD. Relaxin in cardiovascular and renal disease. Kidney Int. 2006; 69: 1498–502.

17. Hewiton TD, Samuel CS. Relaxin: an endogenous renoprotective factor? Ann N Y Acad Sci. 2009; 1160: 289–93.

18. Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest. 1999; 103: 525–33.

19. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012; 380: 756–66.

20. Collins M, Patel NS, Lawrence KM, et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005; 68: 529–36.

21. Collino M, Benetti E, Miglio G, et al. Peroxisome proliferator-activated receptor beta/delta agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic Biol Med. 2011; 50: 345–53.

22. Patel NS, Cuzzocrea S, Collino M, et al. The role of cyclooxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol. 2007; 562: 148–54.

23. Cossum PA, Dwyer KA, Roth M, et al. The disposition of a human relaxin (hRlx-2) in pregnant and nonpregnant rats. Pharm Res. 1992; 9: 419–24.

24. Chen SA, Periman AJ, Spanski N, et al. The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration. Pharm Res. 1993; 10: 834–8.

25. Baccari MC, Nistri S, Vannuccini MG, et al. Reversal by relaxin of altered ileal spontaneous contractions in dystrophic (mdx) mice through a nitric oxide-mediated mechanism. Am J Physiol Regul Integr Comp Physiol. 2007; 293: R682–8.

26. Bazzi C, Petri C, Rizza V, et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant. 2002; 17: 1890–6.

27. Aruoma OI, Halliwell B, Laughton MJ, et al. The mechanism of initiation of lipid peroxidation. Evidence against a requirement for an iron(II)-iron(III) complex. Biochem J. 1989; 258: 617–20.

28. Nishida S, Teramoto K, Kimoto-Kinoshi S, et al. Change of Cu, Zn-superoxide dismutase activity of guinea pig lung in experimental asthma. Free Radic Res. 2002; 36: 601–6.

29. Patel NS, Kerr-Peterson HL, Brines M, et al. Delayed administration of pyroglatemate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med. 2012; 18: 719–27.

30. Samuel CS, Hewittson TD. Relaxin and the progression of kidney disease. Curr Opin Nephrol Hypertens. 2009; 18: 9–14.

31. Nistri S, Cinci L, Perna AM, et al. Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. Pharmacol Res. 2008; 57: 43–8.

32. Cosen-Binker LI, Binker MG, Cosen R, et al. Relaxin prevents the development of severe acute pancreatitis. World J Gastroenterol. 2006; 12: 1558–68.

33. Danielson LA, Conrad KP. Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats. J Appl Physiol. 2003; 95: 1509–14.

34. Smith MC, Danielson LA, Conrad KP, et al. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol. 2006; 17: 3192–7.

35. Brecht A, Bartsch C, Baumann G, et al. Relaxin inhibits early steps in vascular inflammation. Regul Pept. 2011; 166: 76–82.

36. Dschietzig T, Bartsch C, Stangl V, et al. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J. 2004; 18: 1536–8.

37. Vannacci A, Rizza V, et al. Anti-inflammatory actions of recombinant human relaxin. J Cell Mol Med. 2011; 15: 2232–44.

38. Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolism and function in angiotensin II but not N(omega)-nitro-L-arginine methyl ester hypertensive rats. Hypertension. 2011; 58: 197–204.

39. Luque Contreras D, Vargas Robles H, Romo E, et al. The role of nitric oxide in the post-ischemic revascularization process. Pharmaco Ther. 2006; 112: 553–63.

40. Kwon O, Hong SM, Ramesh G. Diminished NO generation by injured endothelium and loss of macula densa nNOS may contribute to sustained acute kidney injury after ischemia-reperfusion. Am J Physiol Renal Physiol. 2009; 296: F125–33.

41. Lopez-Neblina F, Paez AJ, Toledo AH, et al. Role of nitric oxide in ischemia/reperfusion of the rat kidney. Circ Shock. 1994; 44: 91–5.

42. Masini E, Nistri S, Vannucci A, et al. Relaxin inhibits the activation of human neutrophils: involvement of the nitric oxide pathway. Endocrinology. 2004; 145: 1106–12.

43. Bani D, Nistri S, Cinci L, et al. A novel, simple bioactivity assay for relaxin based on inhibition of platelet aggregation. Regul Pept. 2007; 144: 10–6.

44. McGuane JT, Debrah JE, Sautina L, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous
arteries via PI3 kinase and nitric oxide. Endocrinology. 2011; 152: 2786–96.

47. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296: 1655–7.

48. El Eter EA, Aldrees A. Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischaemia-reperfusion injury. Shock. 2012; 37: 639–44.

49. Jang HS, Kim J, Kim KY, et al. Previous ischemia and reperfusion injury results in resistance of the kidney against subsequent ischemia and reperfusion insult in mice: a role for the Akt signal pathway. Nephrol Dial Transplant. 2012; 27: 3762–70.

50. Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995; 270: 1326–31.

51. Hung CC, Ichimura T, Stevens JL, et al. Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation. J Biol Chem. 2003; 278: 29317–26.

52. Chen M, Bao W, Aizman R, et al. Activation of extracellular signal-regulated kinase mediates apoptosis induced by uropathogenic Escherichia coli toxins via nitric oxide synthase: protective role of heme oxygenase-1. J Infect Dis. 2004; 190: 127–35.

53. Mendez N, Abarzua-Catalan L, Vilches N, et al. Timed maternal melatonin treatment reverses circadian disruption of the fetal adrenal clock imposed by exposure to constant light. PLoS ONE. 2012; 7: e42713.

54. Doi M, Shichiri M, Katsuyama K, et al. Cytokine-activated p42/p44 MAP kinase is involved in inducible nitric oxide synthase gene expression independent from NF-kappaB activation in vascular smooth muscle cells. Hypertens Res. 2000; 23: 659–67.

55. Sumi D, Ignarro LJ. Regulation of inducible nitric oxide synthase expression in advanced glycation end-product-stimulated raw 264.7 cells: the role of heme oxygenase-1 and endogenous nitric oxide. Diabetes. 2004; 53: 1841–50.